Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Jul 2026
The newly approved inhibitor is for patients who previously received another drug of the same class.
Read Full News1.
More men with prostate cancer are avoiding unnecessary surgery
2.
Even when they are not paying attention, children are still learning.
3.
FDA Approves New Bladder Cancer First-Line Standard of Care.
4.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
5.
AI is useful in low-resource areas for triaging breast masses.
1.
Community Cancer Awareness Through Survivor Advocacy Networks
2.
Evidence-Based Pathways for Survivorship Care Planning
3.
Red Blood Cell Aging and Clinical Implications
4.
Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options
5.
Clinical Trends in Oncology in Clinical Decision-Making
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Efficient Management of First line ALK-rearranged NSCLC - Part V
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge